FUJIFILM Diosynth Biotechnologies and NeuExcell Therapeutics have entered a manufacturing agreement to advance NXL-001, a potential neuro-regeneration gene therapy to treat ischemic cortical stroke   FUJIFILM Diosynth Biotechnologies (FDB) will provide essential drug substance and drug product manufacturing, under accelerated timelines, for NeuExcell’s first-in-human clinical studies.   Drug substance manufacturing will take place at FDB’s state-of-the-art cGMP mammalian manufacturing ...